Akero Therapeutics, Inc.
AKRO
$54.63
-$0.06-0.11%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -23.44% | -39.08% | -50.30% | -66.09% | -98.29% |
| Total Depreciation and Amortization | 200.00% | 77.78% | -10.53% | -37.93% | -86.49% |
| Total Amortization of Deferred Charges | 29.66% | 39.01% | -15.56% | -22.68% | -27.14% |
| Total Other Non-Cash Items | 49.94% | 36.69% | 47.03% | 49.66% | 20.15% |
| Change in Net Operating Assets | 102.87% | 442.50% | -250.16% | 144.95% | 148.02% |
| Cash from Operations | -18.20% | -32.73% | -68.49% | -58.29% | -73.13% |
| Capital Expenditure | 100.00% | 100.00% | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -197.49% | -1.47% | -253.80% | 51.39% | 67.09% |
| Cash from Investing | -194.84% | -1.14% | -254.34% | 50.94% | 66.79% |
| Total Debt Issued | -100.00% | -100.00% | -100.00% | -33.33% | -33.33% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 32.59% | 33.39% | -31.65% | 28.78% | 1.68% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 28.49% | 14.45% | -53.41% | -8.76% | 94.25% |
| Cash from Financing | 19.05% | 29.86% | -32.71% | 26.19% | 4.17% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -401.02% | 32.81% | -219.70% | 776.48% | 144.49% |